

REMARKS

Favorable reconsideration in view of the herewith presented amendment and remarks is respectfully requested.

In response to the Examiner's objection to claims 10 and 11 as being substantially duplicative, applicants have amended claim 10 to include pharmaceutically acceptable salts. This recitation finds support throughout the instant specification and in claim 1.

Applicants also submit herewith a supplemental Information Disclosure Statement, so that the Examiner has before him the art cited in the US or foreign applications of this or related applications. Applicants do not believe this newly submitted art is pertinent to the patentability of the pending claims, but submit the art in an abundance of caution and to allow the Examiner to reach his own determination.

It is believed that all of the pending claims are in condition for allowance. Early and favorable action by the Examiner is earnestly solicited.

If any further questions arise, the Examiner is invited to call Dorothy Auth at (212) 415-8564.

AUTHORIZATION

The Commissioner is authorized to charge any additional fees which may be required for this amendment, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2976-4032.


In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is

requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 2976-4032. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: June 13, 2001

By: 
Michael S. Marcus
Registration No. 31,727

MORGAN & FINNEGAN
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Telecopier